APA (7th ed.) Citation

Thuluva, S., Paradkar, V., Gunneri, S., Mogulla, R. R., Yerroju, V., Dhar, C., . . . Rao, A. V. (2025). Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: A phase 3, single-blind, randomised controlled trialResearch in context. Elsevier.

Chicago Style (17th ed.) Citation

Thuluva, Subhash, et al. Safety and Immunogenicity of Booster Doses of an XBB.1.5 RBD Subunit COVID-19 Vaccine Among Individuals Aged 5–80 Years in India: A Phase 3, Single-blind, Randomised Controlled TrialResearch in Context. Elsevier, 2025.

MLA (9th ed.) Citation

Thuluva, Subhash, et al. Safety and Immunogenicity of Booster Doses of an XBB.1.5 RBD Subunit COVID-19 Vaccine Among Individuals Aged 5–80 Years in India: A Phase 3, Single-blind, Randomised Controlled TrialResearch in Context. Elsevier, 2025.